ProMIS Neurosciences reports FY 2024 net income $2.8M; Phase 1b PRECISE-AD enrolling

ProMIS Neurosciences Inc.

2025-Q1 EPS reported -$0.21

Cash $13.3M at Dec 31, 2024; PIPE financing provided $30.3M upfront with potential $92.4M from warrants.
R&D expenses $10.6M (up 34% YoY) driven by Phase 1a/1b clinical costs; net income of $2.8M vs loss of $13.2M in 2023.
Gain on change in fair value of warrant liabilities of $22.6M drove net income; operating loss remains.
Phase 1b PRECISE-AD trial (NCT06750432) dosed multiple patients; plans ~100 subjects at 22 US sites.
Interim results from PRECISE-AD expected 1H 2026, topline results by end of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.